Focus

Opthea is committed to improving vision in patients suffering from retinal eye diseases.

We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies.

OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.

LEARN MORE

Disease

Wet AMD is the leading cause of blindness in the developed world in people aged over 50 years. It is caused by the abnormal growth and leakage of blood vessels at the back of the eye, which causes degeneration of the retina and vision loss.

Learn More

Technology

Opthea’s technology is centered on two members of the Vascular Endothelial Growth Factor (VEGF) family of proteins, VEGF-C and VEGF-D, and their activation of VEGF receptors. These proteins promote blood vessel development (angiogenesis) by binding and activating VEGFR-2 and VEGFR-3, and lymphatic vessel development (lymphangiogenesis), by activation of VEGFR-3.

Learn More

Opportunity

Both wet AMD and DME are associated with vascular dysfunction and fluid accumulation at the back of the eye in a region of the central retina or ‘macula’ that is needed for sharp, central vision. Vessel growth and vascular leakage are primarily driven by members of the vascular endothelial growth factor (VEGF) family, which comprises 5 members including VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PlGF).

Learn More

OPT-302

OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Learn More

Clinical Trials

Opthea initiated two pivotal Phase 3 clinical trials for the treatment of wet AMD in the first half of 2021. Opthea has completed three international clinical trials investigating OPT-302 in two disease indications.  Two of the trials were in wet AMD patients including a first in human Phase 1b/2a study followed by  a large randomized controlled Phase 2bstudy, whilst the third trial was aPhase 1b/2a study in patients with DME.

Learn more

WITH CLINICAL TRIALS PROGRESSING
AND DATA LOOKING PROMISING,
WE BELIEVE OPT-302 WILL IMPROVE
OUTCOMES FOR PATIENTS WITH
THESE DEBILITATING DISEASES.

Opthea Researcher

Announcements

Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights

30 August 2022

A clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today reported financial results for the fiscal year ended June 30, 2022.

Read More

Full Report

Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

16 August 2022

The presentation may be accessed for 90 days on the Investors page of the Opthea website

Read More

Webcast

Opthea Successfully Closes Well Supported US$90 Million Equity Financing

15 August 2022

Opthea received binding commitments for a successful two-tranche placement of new fully paid ordinary shares

Read More

Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD

15 August 2022

Today announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics (Launch Tx)

Read More

ALL ANNOUNCEMENTS

Investigating Anti-VEGF-C and -D Therapy in WetAMD